The treatment has been approved for NHS use, offering new hope to the nearly 12,000 people in England living with lupus ...

Dupilumab, a simple pre-filled pen that people inject themselves with every two weeks, is the first biologic that targets both the symptoms of COPD and an underlying cause of the disease. It brings ...

Thousands of people living with advanced prostate cancer will have access to a life-extending new treatment that can be taken at home from today (Friday, 23 January). NICE has recommended talazoparib ...

Accessed via the internet, the online self-help programme is for people who binge eat, particularly those with bulimia nervosa, binge eating disorder, and similar eating problems. It's designed for ...

An online therapy programme can be used to help people aged 16 and over with eating disorders whilst they wait for specialist NHS treatment, an independent NICE has said. As Sam Roberts prepared to ...

There are simple discount patient access schemes for amivantamab (Rybrevant) and lazertinib (Lazcluze). NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS ...

Concizumab for treating haemophilia A or B in people 12 years and over with factor inhibitors (terminated appraisal) TA1124 27 January 2026 27 January 2026 Pembrolizumab with pemetrexed and ...

This guideline covers the care of pregnant women and pregnant trans and non-binary people and their babies during labour and immediately after birth. It focuses on women and pregnant people who give ...

This guideline covers general principles for prescribing and managing withdrawal from opioids, benzodiazepines, gabapentinoids, Z‑drugs and antidepressants in primary and secondary care. It does not ...

This guideline covers recognising, assessing and treating post-traumatic stress disorder (PTSD) in children, young people and adults. It aims to improve quality of life by reducing symptoms of PTSD ...

Evidence-based recommendations on trastuzumab deruxtecan (Enhertu) for treating HER2-positive unresectable or metastatic breast cancer in adults after 2 or more anti-HER2 therapies. Next review: More ...

Decisions about updating our guidance are made by NICE’s prioritisation board. For more information on the principles and process, see NICE-wide topic prioritisation: the manual. For information about ...